On May 23, Novell health and prenetics Group Limited (prenetics) jointly issued a strategic cooperation to promote the listing of Novell health’s product Chang Weiqing in Hong Kong, China and “going to sea” in Southeast Asia.
According to the signed strategic cooperation agreement, Novell health and prenetics will launch in-depth cooperation, fully integrate the high-quality resources of both sides in market and channel expansion and product and service operation, jointly promote the listing and market coverage of Chang Weiqing (KRAS gene mutation, BMP3 / NDRG4 gene methylation and fecal occult blood joint test kit) in Hong Kong, Macao and Taiwan, and plan to explore market opportunities in Southeast Asian countries or regions in the same period.
It is reported that on June 8, Chang Weiqing will be officially listed on the Hong Kong market. During the cooperation period, Chang Weiqing was a colorectal cancer early screening product exclusively cooperated by prenetics.
Based on the profit distribution agreement reached by both parties, Novell health and prenetics will share the profits obtained by Chang Weiqing in the cooperative market in a proportion of 50:50. According to the completed Changweiqing authorization agreement, prenetics has been authorized by nuohui health to provide Changweiqing central laboratory testing services within the specified market scope.
It is reported that prenetics is the world’s leading gene and diagnostic testing company. On May 18, it completed the merger with artisan acquisition Corp. (artisan), successfully listed on the Nasdaq Stock Exchange of the United States, and became an entrepreneurial Unicorn publicly listed in Hong Kong. The company’s pillar product pipeline covers prevention, diagnosis and personalized medical services. Chang Weiqing is the main product of prenetics’ disease prevention product line.
As a cancer early screening molecular testing product approved by the State Drug Administration, Chang Weiqing was independently developed by nuohui health. After seven years of construction, he invested US $100 million and completed China’s first prospective large-scale multi center registered clinical trial of cancer early screening in 16 months. The experimental data showed that the sensitivity of Chang Weiqing to colorectal cancer was 95.5%; The sensitivity of detecting advanced adenoma was 63.5%, which was more than twice higher than the traditional detection of occult blood in stool. It can effectively detect precancerous lesions; The negative predictive value of colorectal cancer is as high as 99.6%, which can minimize the possibility of missed detection. Chang Weiqing’s patented multi-target fecal fit-dna technology has been incorporated into all national colorectal cancer screening and diagnosis and treatment guidelines released so far in China. As of December 31, 2021, Chang Weiqing has rapidly completed the access and sales of more than 400 hospitals within one year after being approved, and has established in-depth strategic cooperation with cross-border head platforms such as e-commerce, insurance and private physical examination. Nuohui health owns the global property rights of Chang Weiqing.
In March 2021, nuohui health officially launched the Dawan district operation center located in Nansha, Guangzhou. Dawan district operation center, with a total area of 1300 square meters, has automatic sample processing and advanced information system, with an annual design capacity of 500000 cancer screening and testing services.
